- Prospective, randomized, international multicenter study - PACE - Prostate Advances in Comparative Evidence - results presented at ESTRO 2021 - Bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment
SUNNYVALE, Calif. , Sept. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Nagoya City University Hospital in Aichi has treated the first cancer patient in Japan using the Radixact ® System with ClearRT ™ helical fan-beam kVCT imaging.
More than 30 Accuray TomoTherapy® and CyberKnife® Platform Systems Are Currently in Use at Unicancer, the Largest Network of Comprehensive Cancer Centers in Europe SUNNYVALE, Calif. , Sept. 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Unicancer has selected
UPPSALA, Sweden , and SUNNYVALE, Calif. , Oct. 4, 2021 /PRNewswire/ -- C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement designed to enhance the Accuray Radixact ® System's ability to treat breast cancer.
SUNNYVALE, Calif. , Oct. 12, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.
SUNNYVALE, Calif. , Oct. 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021 , after the market close on Wednesday, November 3, 2021 . Management will host a conference call to review the
Showcases Multiple Forward-Looking Radiotherapy Solutions Designed to Enhance the Treatment Experience for Medical Care Teams and Their Patients SUNNYVALE, Calif. , Oct. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for
SUNNYVALE, Calif. , Oct. 21, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), today announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021 . Accuray is currently finalizing its financial results for the first quarter of fiscal 2022.
SUNNYVALE, Calif. , Oct. 25, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast
Record Revenue First Quarter Fiscal 2022 SUNNYVALE, Calif. , Nov. 3, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021 . First Quarter Fiscal 2022 Summary Record net revenue of $107.4 million
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
